Neumora Therapeutics, Stock Today
| NMRA Stock | 1.13 0.03 2.59% |
PerformanceVery Weak
| Odds Of DistressLow
|
Neumora Therapeutics, is trading at 1.13 as of the 24th of March 2025, a 2.59% down since the beginning of the trading day. The stock's open price was 1.16. Neumora Therapeutics, has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of September 2023 | Category Healthcare | Classification Health Care |
Neumora Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 161.98 M outstanding shares of which 11.2 M shares are now shorted by private and institutional investors with about 7.25 trading days to cover. More on Neumora Therapeutics,
Moving together with Neumora Stock
Moving against Neumora Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Neumora Stock Highlights
| CEO President | Henry Gosebruch | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsNeumora Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neumora Therapeutics,'s financial leverage. It provides some insight into what part of Neumora Therapeutics,'s total assets is financed by creditors.
| |||||
Neumora Therapeutics, (NMRA) is traded on NASDAQ Exchange in USA. It is located in 490 Arsenal Way, Watertown, MA, United States, 02472 and employs 110 people. Neumora Therapeutics, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 183.04 M. Neumora Therapeutics, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 161.98 M outstanding shares of which 11.2 M shares are now shorted by private and institutional investors with about 7.25 trading days to cover.
Neumora Therapeutics, generates negative cash flow from operations
Check Neumora Therapeutics, Probability Of Bankruptcy
Ownership AllocationNeumora Therapeutics, maintains a total of 161.98 Million outstanding shares. The majority of Neumora Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neumora Therapeutics, to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neumora Therapeutics,. Please pay attention to any change in the institutional holdings of Neumora Therapeutics, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neumora Ownership Details
Neumora Therapeutics, Historical Income Statement
Neumora Stock Against Markets
Neumora Therapeutics, Corporate Management
| Jason JD | Chief Officer | Profile | |
| Nicholas Brandon | Chief Officer | Profile | |
| Amy Sullivan | Senior Resources | Profile | |
| John Reynders | Chief Advisor | Profile | |
| Maryjo ChamberlainTharp | Chief Officer | Profile | |
| Kaya Panandiker | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.